Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a controlled crossover study healthy volunteers received a single oral dose of 75 mg indomethacin, 75 mg sustained-release indomethacin, or the new therapeutic system indomethacin Gits 7/85. Dependence on the time of administration was investigated by comparing the plasma level curves obtained following morning and evening administration of indomethacin and indomethacin Gits. Blood samples were taken at defined intervals following administration for determination of indomethacin plasma levels. To determine urinary excretion of prostaglandin (PG)E2, urine was collected during four consecutive 6 h-clearance periods after administration of the indomethacin preparations. The plasma level curve following administration of indomethacin Gits 7/85 did not exhibit clearly distinct initial peaks and, in contrast to the other drug preparations, remained nearly constant over 10-12 h. Indomethacin induced a significant suppression of urinary PGE2 excretion over a period of 12 h, whereas both sustained release indomethacin and indomethacin Gits 7/85 decreased urinary PGE2 excretion for 18 h. Neither the plasma concentration curve of indomethacin nor the inhibitory effect on urinary PGE2 excretion was dependent on the time of administration. Initial central nervous side effects, such as dizziness, were reported by all volunteers after taking indomethacin and by half of the volunteers following sustained release indomethacin, whereas no adverse effects were observed after administration of indomethacin Gits 7/85. The present study demonstrates that indomethacin Gits 7/85 produces no initial peaks of plasma levels but rather a sustained concentration plateau. The excellent tolerability of indomethacin Gits 7/85 is probably due to the lack of peak plasma concentrations.
 ...
PMID:[Indomethacin kinetics and urinary excretion of prostaglandin E2 following oral administration of various dosage forms of indomethacin]. 658 Jul 89

Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast on/off receptor kinetics. Memantine 20 mg/day significantly slowed the rate of deterioration in outpatients with moderate to severe Alzheimer's disease in a 28-week US randomised, double-blind, placebo-controlled, multicentre study. Memantine 10 mg/day improved measures of dementia in care-dependent inpatients with Alzheimer's disease or vascular dementia in a 12-week randomised, double-blind study. Significantly more memantine than placebo recipients were responders according to Clinical Global Impression of Change scores and the Behavioural Rating Scale for Geriatric Patients Care Dependence subscale. Memantine 20 mg/day significantly improved cognition-related outcomes (cognitive subscale of the Alzheimer's Disease Assessment Scale) in patients with vascular dementia in two 28-week randomised, double-blind, placebo-controlled, multicentre trials. No statistically significant between-group difference was seen in other primary endpoints. Adverse events (incidence in memantine recipients greater than in placebo recipients) occurring in patients with moderately severe to severe dementia included diarrhoea, insomnia, dizziness, headache and hallucination.
 ...
PMID:Memantine. 1271 Aug 65